Repare Therapeutics

Repare Therapeutics is a clinical-stage precision oncology company headquartered in Montréal, Canada, with additional operations in Cambridge, Massachusetts. Founded in 2016, the company develops targeted cancer therapies using a synthetic lethality approach, aiming to exploit specific genetic vulnerabilities in tumor cells. Its proprietary SNIPRx platform enables genome-wide, CRISPR-enabled screening to identify synthetic lethal gene pairs. This platform supports the discovery of highly selective small-molecule inhibitors that target genomic instability, with a focus on DNA damage repair pathways.

The company’s lead candidates include camonsertib, an oral ATR inhibitor in Phase 1/2 trials for tumors with ATM or BRCA1/2 mutations; lunresertib, a PKMYT1 inhibitor in mid-stage development targeting cancers with CCNE1 amplification and certain tumor suppressor losses; RP-1664, a PLK4 inhibitor designed for tumors with TRIM37 alterations; and RP-3467, a Polθ ATPase inhibitor being tested both as monotherapy and in combination with the PARP inhibitor olaparib.

Repare has also expanded its capabilities through partnerships. In 2024, it entered a licensing agreement with DCx Biotherapeutics to apply its discovery platforms to the development of multi-modal antibody-drug conjugates. The company collaborates with leading institutions such as Debiopharm, Bristol-Myers Squibb, and the U.S. National Cancer Institute.

Keywords: Repare Therapeutics, synthetic lethality, SNIPRx, precision oncology, DNA damage repair, camonsertib, lunresertib, PKMYT1 inhibitor, ATR inhibitor, Montreal biotech, targeted cancer therapy, Nasdaq RPTX